Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 8 | 11 | +3 |
| Shares | 64.7K | 103.5K | +38.8K (+60.0%) |
| Value | $332.0K | $455.3K | +$123.3K (+37.1%) |
New holders (4)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| TD Waterhouse Canada Inc. | 30,000 | $138.3K | 0.00% |
| HRT Financial LP | 14,369 | $62.0K | 0.00% |
| Bank of America Corp | 104 | $0 | 0.00% |
| Morgan Stanley | 3 | $0 | 0.00% |
Sold out (1)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 707 | $4.00K |